Significant anti-tumor effect of bevacizumab in treatment of pineal gland glioblastoma multiforme

Joshua Mansour, Braxton Fields, Samuel Macomson, Olivier Rixe

Research output: Contribution to journalArticlepeer-review

7 Scopus citations


Glioblastoma multiforme (GBM) is the most aggressive subtype of malignant gliomas. Current standard treatment for GBM involves a combination of cytoreduction through surgical resection, followed by radiation with concomitant and adjuvant chemotherapy (temozolomide). The role of bevacizumab in the treatment of GBM continues to be a topic of ongoing research and debate. Despite aggressive treatment, these tumors remain undoubtedly fatal, especially in the elderly. Furthermore, tumors present in the pineal gland are extremely rare, accounting for only 0.1–0.4 % of all adult brain tumors, with this location adding to the complexity of treatment. We present a case of GBM, at the rare location of pineal gland, in an elderly patient who was refractory to initial standard of care treatment with radiation and concomitant and adjuvant temozolomide, but who developed a significant response to anti-angiogenic therapy using bevacizumab.

Original languageEnglish (US)
Pages (from-to)395-398
Number of pages4
JournalTargeted Oncology
Issue number4
StatePublished - Dec 20 2014


  • Bevacizumab
  • Glioblastoma multiforme
  • Pineal gland

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Pharmacology (medical)


Dive into the research topics of 'Significant anti-tumor effect of bevacizumab in treatment of pineal gland glioblastoma multiforme'. Together they form a unique fingerprint.

Cite this